CoChat

Pioglitazone and risk of bladder cancer: a meta‐analysis of controlled studies

Ferwana, M., Firwana, B., Hasan, R., Al‐Mallah, M. H., Kim, S., Montori, V. M., Murad, M. H. · 2013 · Diabetic Medicine
Cited by 146

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Aims: Pioglitazone, a thiazolidinedione, was approved for treatment of Type 2 diabetes. However, several observational studies suggest an association of pioglitazone with an increased risk of bladder cancer in patients with diabetes. Therefore, we sought to perform a systematic review and meta‐analysis to evaluate the magnitude of this association and the quality of the supporting evidence. Methods: Electronic databases were queried to identify controlled studies of pioglitazone that measured the risk of bladder cancer. Results: Six studies involving 215 142 patients using pioglitazone were included, with a median period of follow‐up of 44 months. The hazard of developing bladder cancer was significantly higher in patients using pioglitazone (hazard ratio 1.23; 95% CI 1.09–1.39; I2 = 0%) compared with control groups. The risk of bias was moderate across the six studies. Considering an incidence rate of 20.8 per 100 000 person years, the number needed to harm was five additional cases of bladder cancer per 100 000 person years. Conclusions: Patients treated with pioglitazone have a slight increased risk of bladder cancer compared to general population. Patient involvement and weighing treatment benefits versus risks should be discussed with patient toward shared decision. Patients with type 2 diabetes with risk factors, such as family history, smoking, or exposure to certain forms of chemotherapy may need to consider other anti‐hyperglycemic agents. Also, pioglitazone should be discontinued in type 2 diabetes patients with newly diagnosed bladder cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dme.12144

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 21

  1. 10.1210/jc.2009-1974 · DOI
  2. 10.1111/j.1463-1326.2009.01055.x · DOI
  3. Miller JL, 1999, FDA approves pioglitazone for diabetes, Am J Health Syst Pharm, 56, 1698, 10.1093/ajhp/56.17.1698 · doi:10.1093/ajhp/56.17.1698
  4. 10.1111/j.1472-8206.2007.00533.x · doi:10.1111/j.1472-8206.2007.00533.x
  5. 10.1007/s00125-004-1651-9 · DOI
  6. 10.1185/030079906X112732 · DOI
  7. 10.1016/S0149-2918(00)80078-8 · DOI
  8. 10.1093/toxsci/kfp256 · DOI · Paper page
  9. Takeda Pharmaceuticals America Inc, 2009, Actos (Pioglitazone Hydrochloride) Tablets: Full Prescribing Information
  10. FDA, 2011, Drug Safety Communication: Update to Ongoing Safety Review of Actos (Pioglitazone) and Increased Risk of Bladder Cancer
  11. La Caisse nationale de l'assurance maladie (CNAM), 2011, Risque de cancer de la vessie chez les personnes diabétiques traitées par pioglitazone en France : une étude de cohorte sur les données du SNIIRAM (Systéme National d'Information Inter‐régimes de l'Assurance Maladie) et du PMSI (Programme de Médicalisation des Systémes d'Information)
  12. European Medicines Agency, 2011, Update on Ongoing European Review of Pioglitazone‐Containing Medicines
  13. European Medicines Agency, 2011, European Medicines Agency Recommends New Contra‐Indications and Warnings for Pioglitazone to Reduce Small Increased Risk of Bladder Cancer
  14. Higgins JPT, Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0
  15. 10.1136/bmj.327.7414.557 · DOI · Paper page
  16. Erdmann E, 2012, Pioglitazone and bladder malignancy during observational follow‐up of proactive: 6‐year update, Diabetes
  17. 10.1136/bmj.e3645 · DOI · Paper page
  18. Li W, 2012, Pioglitazone and bladder cancer: a propensity score matched cohort study, Br J Clin Pharmacol, 75, 254
  19. 10.1001/jama.2011.1142 · DOI · Paper page
  20. 10.1186/1741-7015-5-17 · DOI · Paper page
  21. 10.1210/jc.2007-1907 · DOI · Paper page

Cited by

See all 146

Metadata

Authors
Ferwana, M., Firwana, B., Hasan, R., Al‐Mallah, M. H., Kim, S., Montori, V. M., & Murad, M. H.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2013-08-18
Volume
30
Issue
9
Pages
1026-1032
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2115060720
Cited by
146
References
11
FWCI
9.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.